论文部分内容阅读
食管癌是严重威胁人类健康的恶性肿瘤之一,同步放、化疗是治疗局部进展期食管癌的标准模式,但食管癌患者放、化疗后仍有复发早和预后差等特点。表皮生长因子受体(epithelial growth factor receptor,EGFR)抑制剂西妥昔单抗联合放疗对局部进展期头颈鳞癌的治疗获得了成功。本文根据西妥昔单抗在食管癌二线治疗、一线治疗及新辅助治疗中的应用情况,对西妥昔单抗治疗食管癌的安全性及疗效进行简要综述,指出西妥昔单抗联合同步放、化疗治疗局部晚期食管癌具有良好的耐受性和近期疗效,尤其是在新辅助治疗中的疗效令人振奋,值得为此开展多中心Ⅲ期临床研究。
Esophageal cancer is a serious threat to human health, one of the malignant tumors, simultaneous radiotherapy and chemotherapy is the standard model for the treatment of locally advanced esophageal cancer, but radiotherapy and chemotherapy in patients with esophageal cancer still have early recurrence and poor prognosis. The treatment of locally advanced head and neck squamous cell carcinoma with epithelial growth factor receptor (EGFR) inhibitor cetuximab in combination with radiotherapy has been successful. This article is based on the application of cetuximab in second-line esophageal cancer treatment, first-line treatment and neoadjuvant therapy, the safety and efficacy of cetuximab in the treatment of esophageal cancer are briefly reviewed, pointing out that cetuximab in combination with synchronization Chemotherapy for locally advanced esophageal cancer has good tolerability and short-term efficacy, especially in neoadjuvant therapy is exciting, it is worth carrying out multi-center phase III clinical studies.